We have a library of helpful resources and scientific content for our lead program, GP-2250. Take a look here: bit.ly/3b6gQeT

#pancsm #PancreaticCancer ​​ #Cancer #Oncology #DisruptingCancersEnergy

MD Anderson recently presented a poster on GP-2250 at #AACR23 titled “Mechanisms and rational combinations with GP-2250, a novel oxathiazine derivative, in ovarian cancer.”

MD Anderson Cancer Center AACR #Cancer #Oncology #DisruptingCancersEnergy #OvarianCancer #ovca #gynca

The pandemic exodus from big cities thinned or reversed course in 2022, recent data suggests.

Our lead therapeutic is being developed for the treatment of ovarian cancer in combination with leading anti-cancer agents based on promising preclinical data.

bit.ly/3S9sjLZ
#Cancer #Oncology #DisruptingCancersEnergy #OvarianCancer #ovca #gynca

Panavance Therapeutics to Present at the Biotechnology Innovation Organization (BIO) International Convention

bit.ly/432vKZJ
#BIO2023 #DisruptingCancersEnergy #Oncology #Cancer #Ovaca #Pancsm #OvarianCancer #PancreaticCancer #Gynaca

We are a dedicated team focused on addressing difficult to treat cancers with a clear unmet need. Learn more about Panavance by visiting bit.ly/3ydJd4c

#Cancer #Oncology #DisruptingCancersEnergy #pancsm #PancreaticCancer #OvarianCancer #ovca #gynca

New hope begins with novel science. Panavance is on a mission to provide both.

bit.ly/3s95sol​​
#PancreaticCancer #Cancer ​ #Oncology #DisruptingCancersEnergy

We believe that our highly tumor cell selective asset may offer a broad benefit across many cancers and in combination with existing treatments. Learn more here: bit.ly/42WsU99

#Cancer #Oncology #DisruptingCancersEnergy #pancsm #PancreaticCancer #OvarianCancer

As this year comes to a close, we reflect on the strides Panavance took in 2022. We look forward to all of the progress to be made in 2023!

#PancreaticCancer #Cancer #Oncology #DisruptingCancersEnergy